Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
OBJECTIVES: To evaluate the discrimination, calibration, and net benefit performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) across five European randomized study of screening for prostate cancer (ERSPC), 1 United Kingdom, 1 Austrian, and 3 US biopsy cohorts. METHODS: PCPTRC...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826289334039347200 |
|---|---|
| author | Ankerst, D Boeck, A Freedland, S Thompson, I Cronin, A Roobol, M Hugosson, J Stephen Jones, J Kattan, M Klein, E Hamdy, F Neal, D Donovan, J Parekh, D Klocker, H Horninger, W Benchikh, A Salama, G Villers, A Moreira, D Schröder, F Lilja, H Vickers, A |
| author_facet | Ankerst, D Boeck, A Freedland, S Thompson, I Cronin, A Roobol, M Hugosson, J Stephen Jones, J Kattan, M Klein, E Hamdy, F Neal, D Donovan, J Parekh, D Klocker, H Horninger, W Benchikh, A Salama, G Villers, A Moreira, D Schröder, F Lilja, H Vickers, A |
| author_sort | Ankerst, D |
| collection | OXFORD |
| description | OBJECTIVES: To evaluate the discrimination, calibration, and net benefit performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) across five European randomized study of screening for prostate cancer (ERSPC), 1 United Kingdom, 1 Austrian, and 3 US biopsy cohorts. METHODS: PCPTRC risks were calculated for 25,733 biopsies using prostate-specific antigen (PSA), digital rectal examination, family history, history of prior biopsy, and imputation for missing covariates. Predictions were evaluated using the areas underneath the receiver operating characteristic curves (AUC), discrimination slopes, chi-square tests of goodness of fit, and net benefit decision curves. RESULTS: AUCs of the PCPTRC ranged from a low of 56% in the ERSPC Goeteborg Rounds 2-6 cohort to a high of 72% in the ERSPC Goeteborg Round 1 cohort and were statistically significantly higher than that of PSA in 6 out of the 10 cohorts. The PCPTRC was well calibrated in the SABOR, Tyrol, and Durham cohorts. There was limited to no net benefit to using the PCPTRC for biopsy referral compared to biopsying all or no men in all five ERSPC cohorts and benefit within a limited range of risk thresholds in all other cohorts. CONCLUSIONS: External validation of the PCPTRC across ten cohorts revealed varying degree of success highly dependent on the cohort, most likely due to different criteria for and work-up before biopsy. Future validation studies of new calculators for prostate cancer should acknowledge the potential impact of the specific cohort studied when reporting successful versus failed validation. |
| first_indexed | 2024-03-07T02:27:17Z |
| format | Journal article |
| id | oxford-uuid:a60de66b-a50f-4129-a85d-91bcd3fcd809 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:27:17Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:a60de66b-a50f-4129-a85d-91bcd3fcd8092022-03-27T02:44:36ZEvaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a60de66b-a50f-4129-a85d-91bcd3fcd809EnglishSymplectic Elements at Oxford2012Ankerst, DBoeck, AFreedland, SThompson, ICronin, ARoobol, MHugosson, JStephen Jones, JKattan, MKlein, EHamdy, FNeal, DDonovan, JParekh, DKlocker, HHorninger, WBenchikh, ASalama, GVillers, AMoreira, DSchröder, FLilja, HVickers, AOBJECTIVES: To evaluate the discrimination, calibration, and net benefit performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) across five European randomized study of screening for prostate cancer (ERSPC), 1 United Kingdom, 1 Austrian, and 3 US biopsy cohorts. METHODS: PCPTRC risks were calculated for 25,733 biopsies using prostate-specific antigen (PSA), digital rectal examination, family history, history of prior biopsy, and imputation for missing covariates. Predictions were evaluated using the areas underneath the receiver operating characteristic curves (AUC), discrimination slopes, chi-square tests of goodness of fit, and net benefit decision curves. RESULTS: AUCs of the PCPTRC ranged from a low of 56% in the ERSPC Goeteborg Rounds 2-6 cohort to a high of 72% in the ERSPC Goeteborg Round 1 cohort and were statistically significantly higher than that of PSA in 6 out of the 10 cohorts. The PCPTRC was well calibrated in the SABOR, Tyrol, and Durham cohorts. There was limited to no net benefit to using the PCPTRC for biopsy referral compared to biopsying all or no men in all five ERSPC cohorts and benefit within a limited range of risk thresholds in all other cohorts. CONCLUSIONS: External validation of the PCPTRC across ten cohorts revealed varying degree of success highly dependent on the cohort, most likely due to different criteria for and work-up before biopsy. Future validation studies of new calculators for prostate cancer should acknowledge the potential impact of the specific cohort studied when reporting successful versus failed validation. |
| spellingShingle | Ankerst, D Boeck, A Freedland, S Thompson, I Cronin, A Roobol, M Hugosson, J Stephen Jones, J Kattan, M Klein, E Hamdy, F Neal, D Donovan, J Parekh, D Klocker, H Horninger, W Benchikh, A Salama, G Villers, A Moreira, D Schröder, F Lilja, H Vickers, A Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. |
| title | Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. |
| title_full | Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. |
| title_fullStr | Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. |
| title_full_unstemmed | Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. |
| title_short | Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. |
| title_sort | evaluating the pcpt risk calculator in ten international biopsy cohorts results from the prostate biopsy collaborative group |
| work_keys_str_mv | AT ankerstd evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT boecka evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT freedlands evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT thompsoni evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT cronina evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT roobolm evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT hugossonj evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT stephenjonesj evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT kattanm evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT kleine evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT hamdyf evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT neald evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT donovanj evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT parekhd evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT klockerh evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT horningerw evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT benchikha evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT salamag evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT villersa evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT moreirad evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT schroderf evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT liljah evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup AT vickersa evaluatingthepcptriskcalculatorinteninternationalbiopsycohortsresultsfromtheprostatebiopsycollaborativegroup |